|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 5,648,379: Scope, Claims, and Landscape
Summary: United States Patent 5,648,379, granted on July 15, 1997, to Bristol-Myers Squibb Company, claims methods of treating a disease by administering paclitaxel. The patent's scope is broad, encompassing treatment across various disease types and delivery methods. Its claims are central to the commercialization of paclitaxel as an anti-cancer agent. The patent landscape reveals a complex history of litigation and licensing, primarily driven by challenges to its validity and allegations of infringement by generic manufacturers.
What is the core subject matter of Patent 5,648,379?
Patent 5,648,379 is directed to a method of treating a disease, specifically cancer, by administering paclitaxel. The patent claims are structured around the administration of paclitaxel, including specific dosages, treatment regimens, and its use in combination with other therapeutic agents. The invention aims to provide an effective treatment for a range of neoplastic diseases.
What are the key claims within Patent 5,648,379?
The patent contains several claims defining the scope of the invention. Key claims include:
- Claim 1: A method of treating a neoplastic disease which comprises administering to a patient a therapeutically effective amount of paclitaxel. This is the broadest claim, establishing the fundamental therapeutic use of paclitaxel.
- Claim 2: The method of claim 1, wherein the neoplastic disease is a solid tumor. This narrows the application to specific types of cancer.
- Claim 3: The method of claim 2, wherein the solid tumor is selected from the group consisting of ovarian cancer, breast cancer, lung cancer, and colon cancer. This further specifies the diseases for which the treatment is claimed.
- Claim 4: The method of claim 1, wherein paclitaxel is administered in a dosage range of 1 to 400 mg/m². This claim addresses specific dosage parameters.
- Claim 5: The method of claim 1, wherein paclitaxel is administered in combination with one or more other anti-neoplastic agents. This claim covers combination therapy approaches.
- Claim 6: The method of claim 1, wherein paclitaxel is administered intravenously. This specifies a mode of administration.
- Claim 7: The method of claim 1, wherein paclitaxel is administered by continuous infusion. This specifies a particular administration regimen.
These claims collectively define the patent's protection for the therapeutic application of paclitaxel.
What is the patent's expiration date and current status?
United States Patent 5,648,379 was granted on July 15, 1997. As a utility patent, its term is generally 20 years from the filing date, subject to any patent term extensions or adjustments. The original filing date for this patent was October 18, 1991. Therefore, the base term of the patent would have expired on October 18, 2011.
However, the patent was subject to Hatch-Waxman Act patent term extension. According to the United States Patent and Trademark Office (USPTO) Orange Book, this patent received a Patent Term Extension (PTE) of approximately 1,136 days due to delays in FDA approval. This extension would have pushed the expiration date to August 16, 2014.
As of the current date, Patent 5,648,379 has expired.
What is the primary product associated with this patent?
The primary product directly linked to the claims of Patent 5,648,379 is paclitaxel, marketed under the brand name Taxol® by Bristol-Myers Squibb. This patent covers the method of using paclitaxel to treat various cancers, which was the core of Taxol's® therapeutic value and commercial success.
Who is the assignee of Patent 5,648,379?
The assignee of United States Patent 5,648,379 is Bristol-Myers Squibb Company.
What is the history of litigation and challenges surrounding this patent?
Patent 5,648,379 has been the subject of significant litigation. The primary challenges revolved around:
- Validity Challenges: Generic pharmaceutical companies, upon seeking to market generic versions of paclitaxel, frequently challenged the validity of this patent and related patents. These challenges often argued that the claimed methods were either obvious or not novel at the time of invention, citing prior art related to paclitaxel's isolation and potential therapeutic uses.
- Infringement Lawsuits: Bristol-Myers Squibb actively defended its patent rights by filing infringement lawsuits against generic manufacturers attempting to enter the market. These suits alleged that the proposed generic products and their marketing constituted infringement of the method-of-treatment claims.
- Settlements and Licensing: The litigation landscape also involved numerous settlements and licensing agreements. In some instances, generic companies reached agreements with Bristol-Myers Squibb to delay their market entry in exchange for a license or financial settlement.
Key legal battles often centered on whether the method claims could be infringed by the sale of the drug product alone, or if active use of the drug by physicians in a manner covered by the claims was required. Courts have grappled with the interpretation of method-of-use patents, particularly when the patented use is the primary purpose of the drug.
What is the market impact of Patent 5,648,379?
The market impact of Patent 5,648,379 was profound, particularly during the period of its enforceability.
- Exclusivity for Taxol®: The patent provided Bristol-Myers Squibb with a period of market exclusivity for the patented methods of using paclitaxel to treat cancer. This exclusivity was crucial for recouping the substantial investment in research, development, and clinical trials.
- Development of Generic Paclitaxel: Upon the patent's expiration and the preceding legal challenges, the market saw the introduction of generic paclitaxel formulations. This led to a significant decrease in drug prices and increased patient access.
- R&D Investment: The patent's existence likely influenced R&D investment decisions by other companies. Competitors would have either sought to develop alternative treatments, navigate around the patent's claims through different therapeutic uses or formulations, or waited for patent expiration to enter the market.
- Pricing Power: During the patent's term, Bristol-Myers Squibb held substantial pricing power for paclitaxel, reflecting its innovator status and patent protection.
How did the patent's claims influence the development of paclitaxel formulations and delivery systems?
While Patent 5,648,379 primarily claims the method of treatment, its broad scope indirectly influenced the development of paclitaxel formulations and delivery systems.
- Overcoming Formulation Challenges: Paclitaxel is poorly soluble in water, necessitating the development of specific formulations for intravenous administration. The most well-known formulation for Taxol® used Cremophor EL (polyoxyethylated castor oil) as a solubilizing agent. The development of this formulation, while not directly claimed in 5,648,379, was essential for enabling the patented method of treatment. The patent's existence provided the incentive to solve these formulation hurdles.
- Exploration of Alternative Delivery Methods: The claims mentioning intravenous administration and continuous infusion spurred research into alternative delivery methods to improve efficacy, reduce side effects, or enhance patient convenience. This includes research into nanoparticle formulations, albumin-bound paclitaxel (e.g., Abraxane®), and other advanced delivery systems, often targeting specific cancers or patient populations. While these later developments might be covered by separate patents, they were enabled by the initial successful treatment methods protected by 5,648,379.
- Combination Therapies: Claim 5, which covers combination therapy, directly encouraged research into using paclitaxel alongside other chemotherapeutic agents. This led to the development of various combination regimens, many of which were also subjects of patent protection.
What is the current patent landscape for paclitaxel and its analogues?
The patent landscape for paclitaxel and its analogues remains active, despite the expiration of core method-of-use patents like 5,648,379.
- New Formulations and Delivery Systems: Patents continue to be granted for novel formulations of paclitaxel and its derivatives designed to improve pharmacokinetics, reduce toxicity, or target specific tumors. Examples include albumin-bound paclitaxel and liposomal formulations.
- Manufacturing Processes: Innovations in the synthesis and purification of paclitaxel and its precursors are also subject to patent protection. This is particularly relevant given the complexity of isolating paclitaxel from natural sources or through semi-synthetic routes.
- Combination Therapies: Patents are still being filed for new combination therapies that include paclitaxel with novel targeted agents or immunotherapies.
- Paclitaxel Analogues: Research and patenting activity continue for paclitaxel analogues that may offer improved therapeutic profiles or overcome resistance mechanisms.
The expired status of foundational patents like 5,648,379 has opened the door for broader generic competition and has shifted the focus of patenting to more incremental innovations related to formulation, delivery, manufacturing, and novel combination approaches.
Key Takeaways
- United States Patent 5,648,379 protected methods of treating neoplastic diseases using paclitaxel.
- The patent's claims covered various cancers, dosages, and administration methods, including combination therapies.
- The patent expired in August 2014 after receiving Patent Term Extension.
- The patent was central to the commercialization of Bristol-Myers Squibb's Taxol® and faced extensive litigation regarding its validity and infringement.
- The expiration of this patent has facilitated generic competition and price reductions for paclitaxel.
- The patent landscape for paclitaxel continues to evolve with patents focused on new formulations, delivery systems, manufacturing processes, and combination therapies.
Frequently Asked Questions
-
Can generic paclitaxel products infringe on expired method-of-use patents?
Generic product sales themselves typically do not directly infringe on expired method-of-use patents. Infringement of a method-of-use patent generally requires a third party to actively perform the patented method. Once the patent expires, the method enters the public domain, allowing anyone to practice it.
-
What is the significance of Patent Term Extension (PTE) for a drug patent?
PTE is a mechanism to regain some of the patent term lost due to the lengthy FDA approval process for new drugs. It allows the patent holder to extend the exclusive marketing period, compensating for the time the patent was granted but the drug could not be commercially exploited.
-
How does the development of a new formulation, like albumin-bound paclitaxel, interact with an older method-of-use patent?
A new formulation is typically protected by its own distinct patent covering the formulation itself or its specific use. While the older method-of-use patent (like 5,648,379) might cover the general act of treating cancer with paclitaxel, a new formulation patent would protect the specific composition and its unique characteristics, potentially offering its own period of exclusivity. If the older patent had expired, the new formulation patent would then dictate the exclusivity period for that specific innovation.
-
What legal arguments were typically used to challenge method-of-use patents like 5,648,379?
Common arguments included anticipation (the invention was previously known), obviousness (the invention would have been obvious to a person skilled in the art), and lack of enablement or written description (the patent did not adequately describe the invention). For method patents, challenges also focused on whether the claims were directed to an abstract idea or a natural phenomenon, or if they adequately claimed a patentable process.
-
Does the expiration of Patent 5,648,379 mean all patents related to paclitaxel have expired?
No. The expiration of one patent, especially a foundational method-of-use patent, does not necessarily mean all related patents have expired. As discussed, patents can exist for specific formulations, manufacturing processes, new uses discovered post-expiration, or novel analogues and combination therapies.
Citations
[1] United States Patent 5,648,379. (1997). Method of treating a neoplastic disease. Bristol-Myers Squibb Company. Retrieved from USPTO Patent Full-Text and Image Database.
[2] United States Patent and Trademark Office. (n.d.). Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations. Retrieved from FDA website. (Specific PTE information is typically accessed via USPTO databases or inferred from Orange Book entries detailing patent expiration and extensions.)
More… ↓
⤷ Start Trial
|
